نتایج جستجو برای: fulvestrant

تعداد نتایج: 782  

This paper describes two rapid, sensitive and specific methods for the determination of fulvestrant in pharmaceutical preparations by high performance liquid chromatography (HPLC) and linear sweep voltammetry (LSV). HPLC method was used to study the degradation behaviour. Fulvestrant was subjected to degradation under the conditions of hydrolysis (acid and alkali), oxidation (30% H2O2). The lin...

2008
Luciana F. Macedo Gauri J. Sabnis Olga G. Goloubeva Angela Brodie

Although the aromatase inhibitor anastrozole has been shown to be very effective in the treatment of hormone-dependent postmenopausal breast cancer, some patients with advanced disease will develop resistance to treatment. To investigate therapeutic strategies to overcome resistance to anastrozole treatment, we have used an intratumoral aromatase model that simulates postmenopausal breast cance...

Journal: :Cancer research 2008
Luciana F Macedo Gauri J Sabnis Olga G Goloubeva Angela Brodie

Although the aromatase inhibitor anastrozole has been shown to be very effective in the treatment of hormone-dependent postmenopausal breast cancer, some patients with advanced disease will develop resistance to treatment. To investigate therapeutic strategies to overcome resistance to anastrozole treatment, we have used an intratumoral aromatase model that simulates postmenopausal breast cance...

2017
Tomás Reinert Carlos H. Barrios

We reviewed randomized phase II/III trials comparing first- or second-line endocrine therapy as monotherapy or in combination with targeted therapies for treatment of postmenopausal patients with hormone receptor-positive advanced breast cancer. First-line was defined as treatment for endocrine therapy-naïve advanced breast cancer or advanced disease treated with endocrine therapy in the adjuva...

Journal: :World Journal of Surgical Oncology 2008
Jasmine YM Tang Rajendra Singh Rampaul Kwok L Cheung

BACKGROUND The role of fulvestrant in the management of intestinal obstruction associated with lobular carcinoma has not been specifically described. CASE PRESENTATION Herein we present two cases where fulvestrant, as the only available parenteral endocrine agent for postmenopausal advanced breast cancer has the opportunity to provide a means to initiate treatment in those patients who presen...

Journal: :Endocrine-related cancer 2006
K L Cheung R Owers J F R Robertson

The pure anti-oestrogen fulvestrant has now been licensed for use in advanced breast cancer which has progressed on an anti-oestrogen. Optimal sequencing of various endocrine agents becomes very important in the therapeutic strategy. We report our experience of further endocrine response with another endocrine agent after prior fulvestrant treatment. Among all patients with advanced breast canc...

2015
Matthew J. Ellis Antonio Llombart-Cussac David Feltl John A. Dewar Marek Jasiówka Nicola Hewson Yuri Rukazenkov John F.R. Robertson

PURPOSE To compare overall survival (OS) for fulvestrant 500 mg versus anastrozole as first-line endocrine therapy for advanced breast cancer. PATIENTS AND METHODS The Fulvestrant First-Line Study Comparing Endocrine Treatments (FIRST) was a phase II, randomized, open-label, multicenter trial. Postmenopausal women with estrogen receptor-positive, locally advanced/metastatic breast cancer who ...

2013
Wei-Lan Yeh Keiko Shioda Kathryn R. Coser Danielle Rivizzigno Kristen R. McSweeney Toshi Shioda

Fulvestrant is a representative pure antiestrogen and a Selective Estrogen Receptor Down-regulator (SERD). In contrast to the Selective Estrogen Receptor Modulators (SERMs) such as 4-hydroxytamoxifen that bind to estrogen receptor α (ERα) as antagonists or partial agonists, fulvestrant causes proteasomal degradation of ERα protein, shutting down the estrogen signaling to induce proliferation ar...

Journal: :The New England journal of medicine 2015
Nicholas C Turner Cynthia Huang Bartlett Massimo Cristofanilli

BACKGROUND Growth of hormone-receptor-positive breast cancer is dependent on cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), which promote progression from the G1 phase to the S phase of the cell cycle. We assessed the efficacy of palbociclib (an inhibitor of CDK4 and CDK6) and fulvestrant in advanced breast cancer. METHODS This phase 3 study involved 521 patients with advanced hormone-rece...

Journal: :Oncology reports 2009
Takaaki Yoneya Toshiaki Tsunenari Kenji Taniguchi Yoshitake Kanbe Kazumi Morikawa Hisafumi Yamada-Okabe Yeon-Ho Lee Mee-Hyun Lee Lae-Sung Kwon

We compared the antitumor efficacy and estrogen receptor (ER) degradation of CH4893237, a new orally active selective ER downregulator, with fulvestrant and tamoxifen in human breast cancer xenografts with low levels of serum estrogen (E2) (50.6, 22.9 and <16.7 pg/ml), equivalent to the ranges in postmenopausal or aromatase inhibitor-treated breast cancer patients. In addition, using proteolysi...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید